MX337419B - Metodos y composiciones para aplicar moxifloxacina al oido. - Google Patents

Metodos y composiciones para aplicar moxifloxacina al oido.

Info

Publication number
MX337419B
MX337419B MX2012007928A MX2012007928A MX337419B MX 337419 B MX337419 B MX 337419B MX 2012007928 A MX2012007928 A MX 2012007928A MX 2012007928 A MX2012007928 A MX 2012007928A MX 337419 B MX337419 B MX 337419B
Authority
MX
Mexico
Prior art keywords
moxifloxacin
ear
tympanic membrane
methods
compositions
Prior art date
Application number
MX2012007928A
Other languages
English (en)
Other versions
MX2012007928A (es
Inventor
G Michael Wall
Ronald J Sawchuk
Belinda W Y Cheung
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44306169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX337419(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of MX2012007928A publication Critical patent/MX2012007928A/es
Publication of MX337419B publication Critical patent/MX337419B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describen métodos y materiales útiles para aplicar moxifloxacina al oído. Los métodos implican suministrar una composición que contenga al menos un agente viscogénico y moxifloxacina o una sal de la misma a la superficie epidérmica de la membrana timpánica vía el canal auditivo. La composición se suministra a la membrana timpánica en una forma de fluido y, después del suministro a la membrana timpánica, se torna suficientemente viscosa de tal forma que la moxifloxacina se localice en contra de la membrana timpánica. Estas composiciones se pueden utilizar para tratar profiláctica y/o terapéuticamente las condiciones del oído medio e interno, entre las que se incluyen la otitis media.
MX2012007928A 2010-01-07 2011-01-07 Metodos y composiciones para aplicar moxifloxacina al oido. MX337419B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29301910P 2010-01-07 2010-01-07
PCT/US2011/020531 WO2011085209A2 (en) 2010-01-07 2011-01-07 Methods and compositions for applying moxifloxacin to the ear

Publications (2)

Publication Number Publication Date
MX2012007928A MX2012007928A (es) 2012-11-22
MX337419B true MX337419B (es) 2016-03-03

Family

ID=44306169

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007928A MX337419B (es) 2010-01-07 2011-01-07 Metodos y composiciones para aplicar moxifloxacina al oido.

Country Status (23)

Country Link
US (1) US20120289541A1 (es)
EP (2) EP3305280A1 (es)
JP (3) JP2013516485A (es)
KR (2) KR101835895B1 (es)
CN (2) CN102791270A (es)
AU (1) AU2011204275B2 (es)
BR (1) BR112012016809A2 (es)
CA (1) CA2786525A1 (es)
CL (1) CL2012001835A1 (es)
CY (1) CY1119493T1 (es)
DK (1) DK2521547T3 (es)
ES (1) ES2644826T3 (es)
HR (1) HRP20171592T1 (es)
HU (1) HUE035586T2 (es)
LT (1) LT2521547T (es)
MX (1) MX337419B (es)
NO (1) NO2521547T3 (es)
PL (1) PL2521547T3 (es)
PT (1) PT2521547T (es)
RU (2) RU2576029C2 (es)
SI (1) SI2521547T1 (es)
WO (1) WO2011085209A2 (es)
ZA (1) ZA201205965B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
ES2904329T3 (es) * 2012-06-28 2022-04-04 The Administrators Of The Tulane Educational Fund Composiciones selectivamente polimerizables
CN103869033B (zh) * 2012-12-14 2016-10-05 南京长澳医药科技有限公司 一种液相色谱法分离测定盐酸莫西沙星及其杂质的方法
JP6255134B1 (ja) * 2016-11-02 2017-12-27 ヴェローチェ・バイオファーマ・エルエルシー 耳炎の治療のための組成物および方法
CA3084807A1 (en) * 2017-12-08 2019-06-13 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN108593696B (zh) * 2018-04-26 2020-11-03 南京明捷生物医药检测有限公司 一种利用定量核磁测定多肽中三氟乙酸残留的方法
CN117045593B (zh) * 2023-09-19 2024-05-28 上海市第六人民医院 一种用于慢性中耳炎治疗的抗菌温敏水凝胶及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
AR020661A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
KR20070089222A (ko) * 2004-12-10 2007-08-30 알콘, 인코퍼레이티드 귀 감염을 치료하기 위한 조성물
WO2009142719A2 (en) * 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof

Also Published As

Publication number Publication date
CL2012001835A1 (es) 2013-03-22
US20120289541A1 (en) 2012-11-15
EP2521547A4 (en) 2014-03-26
NO2521547T3 (es) 2018-01-13
CA2786525A1 (en) 2011-07-14
EP2521547B1 (en) 2017-08-16
CY1119493T1 (el) 2018-03-07
ZA201205965B (en) 2014-01-29
RU2012133568A (ru) 2014-02-20
EP2521547A2 (en) 2012-11-14
HRP20171592T1 (hr) 2018-02-09
SI2521547T1 (en) 2018-02-28
AU2011204275A1 (en) 2012-08-23
LT2521547T (lt) 2017-12-11
CN106309356A (zh) 2017-01-11
ES2644826T3 (es) 2017-11-30
JP2016155808A (ja) 2016-09-01
CN102791270A (zh) 2012-11-21
WO2011085209A3 (en) 2011-11-17
EP3305280A1 (en) 2018-04-11
RU2576029C2 (ru) 2016-02-27
PT2521547T (pt) 2017-11-17
HUE035586T2 (en) 2018-05-28
DK2521547T3 (da) 2017-11-20
MX2012007928A (es) 2012-11-22
KR20180027611A (ko) 2018-03-14
BR112012016809A2 (pt) 2017-09-26
KR101835895B1 (ko) 2018-03-07
KR20120114344A (ko) 2012-10-16
WO2011085209A2 (en) 2011-07-14
JP2013516485A (ja) 2013-05-13
AU2011204275B2 (en) 2015-04-02
RU2016101214A (ru) 2018-11-21
JP2018076352A (ja) 2018-05-17
PL2521547T3 (pl) 2018-01-31
JP6267246B2 (ja) 2018-01-24

Similar Documents

Publication Publication Date Title
MX337419B (es) Metodos y composiciones para aplicar moxifloxacina al oido.
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12015501738A1 (en) Androgen receptor modulators and uses thereof
MX2010014041A (es) Una forma cristalina de posaconazol.
HK1220631A1 (zh) 用於遞送治療劑的陰離子核心組合物以及製備和使用所述組合物的方法
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
JO3078B1 (ar) مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
EP2044108A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND TREATMENT OF ISCHEMIC SUDIDS AND METHOD FOR THEIR ADMINISTRATION
MX359639B (es) Metodos y composiciones para uso en tratamientos celulares.
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
MX2010004953A (es) Formulaciones de solucion oftalmica u otica topicas que contienen clorihidrato de moxifloxacina y fosfato de dexametasona.
AU2008321142A8 (en) Heterocyclic derivatives as modulators of ion channels
MX2013004693A (es) Composiciones de aripiprazol y metodos para su suministro transdermico.
MX345656B (es) (piridin-4-il)bencilamidas como moduladores alostericos de nachr alfa 7.
EP2583969A4 (en) NEW RHODANINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS WITH THE RHODANIN DERIVATIVES AS ACTIVE AGENTS
ZA201203028B (en) Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin
WO2014169920A3 (en) Use of a microbial composition for the degradation of keratinaceous materials
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
EP3752601A4 (en) ANTI-FOXP3 DRUG COMPOSITIONS AND METHODS OF USE FOR ADOPTIVE CELL THERAPY
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
GB2510314A (en) Antiseptic chewing gum
MX365285B (es) Complejo lubricante para la boca.
EP3823674A4 (en) CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF
WO2015060702A8 (en) Pharmaceutical composition for controlling body mass gain comprising s-phenotropil

Legal Events

Date Code Title Description
FG Grant or registration